bio

This LA Times article describes the success of biotech companies in California and the more recent trend of alliances between smaller and larger biotech companies.

This report is a summation of discussions with leaders in the biomedical research and development field, and the resulting recommendations that could help increase funding and accelerate the finding of cures for those with life-threatening illnesses.

This report is a compilation of two independent studies conducted during 2005-2006. One study compared Minnesota’s biobusiness sector to 10 other states with similar biobusiness economic growth goals. The other study generated a census of Minnesota’s for-profit and not-for-profit organizations in both industry and academia. The study finds that the Minnesota economy is more dependent upon biobusiness than other states, but is not currently investing enough to remain competitive in the coming years.

This paper reviews how research collaborations between dedicated biotechnology firms and multinational pharmaceutical companies have changed over the past 25 years. A discussion of the impact that developments in the biotechnology have had on the process of pharmaceutical R&D will set the context for reviewing the various theoretical approaches used to analyse and understand these alliances, identifying changes in the nature of alliances over time and indicating the future in store for dedicated biotechnology firms.

The purpose of this paper is to explore the role of public policy in promoting interorganisational knowledge links in the biotechnology sector. The paper identifies four main types of knowledge exchange, including market relations, spillovers, formal co-operations and
informal networking. Drawing on evidence from the Vienna biotechnology cluster, the authors intend
to show how national and regional policy programmes and government actions function as mechanisms to stimulate the establishment of such interactions.

This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries - Belgium, Finland, France, Germany, Japan, the Netherlands, Norway and Spain. The report summarises the results of in-depth studies, providing a comparative analysis of participating countries performance in science and innovation in biopharmaceuticals. It highlights specific characteristics of the national biopharmaceutical innovation systems in terms of their international openness and the specific role of demand-side factors in the innovation process.

This report provides comprehensive data, in-depth analysis, market insights, and key trends for the biotechnology sector, as well as a special timeline charting the industry’s long-term evolution. It also provides a strategic view of biotechnology at a global level and insights into major regional markets, including the Americas, Asia-Pacific, and Europe.

This report is a follow-up to a 2004 report in which the authors developed data to measure the size, composition, and geographic distribution of the biosciences across the country. In an effort to understand how and where the bioscience sector is growing and how public policy is supporting this growth, the 2006 report presents updated data, examines trends, and identifies metropolitan areas with the largest and most concentrated employment in each of the biosciences subsectors.

In this paper, the authors propose using SEA in a policy research and priority setting process regarding new technologies, taking the development of Genetically Modified Organisms (GMOs) as an example.

ETLA, the Research Institute of the Finnish Economy, conducted surveys at the end of 2004 and at the beginning of 2002 on the enterprises listed in the Index
of Biotechnology Companies in the Finnish Bioindustries organization. The surveys provide data on financial accounting, R&D activities, intellectual property rights, and sales forecasts.